1. Home
  2. NPWR vs ENGN Comparison

NPWR vs ENGN Comparison

Compare NPWR & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NET Power Inc.

NPWR

NET Power Inc.

HOLD

Current Price

$1.23

Market Cap

137.0M

Sector

Energy

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

SELL

Current Price

$1.75

Market Cap

117.2M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
NPWR
ENGN
Founded
2010
1999
Country
United States
Canada
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
137.0M
117.2M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
NPWR
ENGN
Price
$1.23
$1.75
Analyst Decision
Strong Buy
Hold
Analyst Count
5
10
Target Price
$2.85
★ $3.29
AVG Volume (30 Days)
519.2K
★ 724.6K
Earning Date
11-12-2026
09-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 56.85
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.29
$1.40
52 Week High
$5.20
$12.25

Technical Indicators

Market Signals
Indicator
NPWR
ENGN
Relative Strength Index (RSI) 25.91 38.18
Support Level N/A $1.67
Resistance Level $1.84 $1.84
Average True Range (ATR) 0.08 0.08
MACD -0.06 -0.02
Stochastic Oscillator 1.45 0.00

Price Performance

Historical Comparison
NPWR
ENGN

About NPWR NET Power Inc.

NET Power Inc is a clean energy technology company that has developed a novel power generation system, which it refers to as the NET Power Cycle, designed to produce clean, reliable, and low-cost electricity from natural gas while capturing virtually all atmospheric emissions. Its business model is to license its technology to customers and enable them to build, own, and operate facilities that utilize the Net Power Cycle. The company has conducted a successful demonstration of its technology at the La Porte Demonstration Facility and is developing a utility-scale power plant in Texas named Project Permian.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: